Skip to content
OpenCapital
Get started

Trevi Therapeutics, Inc. TRVI Other Commercial Liabilities

Other financials

Income statement

See full
Operating income-$14.9M-30.0%
Net income-$13.2M-27.6%
EPS (diluted)-$0.090.0%

Balance sheet

See full
Cash & equivalents$19.4M+0.2%
Total debt$682.0K-28.7%
Total equity$172.1M+73.1%
Total assets$179.6M+67.8%

Cash flow

See full
Operating cash flow-$16.7M-23.8%
CapEx$102.0K—
Free cash flow-$16.8M—

Valuation

See full
Market cap$2.47B+152%
Enterprise value$2.45B+157%

Returns & leverage

See full
Return on equity-33.6%-9.4pp
Debt / equity0×0.0×
Current ratio24.8×+9.4×

Where this comes from

Reported directly by Trevi Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Trevi Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Trevi Therapeutics, Inc.'s other commercial liabilities.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Trevi Therapeutics, Inc.'s other commercial liabilities?
Trevi Therapeutics, Inc. (TRVI) reported other commercial liabilities of $4.58M in Q1 2026.
How has Trevi Therapeutics, Inc.'s other commercial liabilities changed year-over-year?
Trevi Therapeutics, Inc.'s other commercial liabilities decreased by 11.4% year-over-year, from $5.17M to $4.58M.
What is the long-term trend for Trevi Therapeutics, Inc.'s other commercial liabilities?
Over 5 years (2020 to 2025), Trevi Therapeutics, Inc.'s other commercial liabilities has grown at a 10.1% compound annual growth rate (CAGR), from $3.43M to $5.53M.